CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Adaptimmune Therapeutics PLC - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Adaptimmune Therapeutics PLC - ADR
60 Jubilee Avenue, Milton Park
Phone: +44 1235430000p:+44 1235430000 ABINGDON, OX14 4RX  United Kingdom Ticker: ADAPADAP

Business Summary
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board David M.Mott 57 1/1/2017 9/1/2014
Chief Executive Officer, Director AdrianRawcliffe 50 9/1/2019 3/1/2015
Chief Financial Officer Gavin H.Wood 53 4/1/2020 4/1/2020
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
TCR2 Therapeutics Inc. 100 Binney St CAMBRIDGE MA United States
Adaptimmune LLC 351 Rouse Boulevard Philadalphia PA United States

Business Names
Business Name
ADAP
Adaptimmune B.V.
Adaptimmune Limited
7 additional Business Names available in full report.

General Information
Number of Employees: 449 (As of 12/31/2023)
Outstanding Shares: 1,480,950,456 (As of 3/4/2024)
Shareholders: 27
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024